Favorable pregnancy outcome following Trastuzumab (Herceptin®) use during pregnancy-Case report and updated literature review

Alon Shrim, Facundo Garcia-Bournissen, Cynthia Maxwell, Dan Farine, Gideon Koren

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Background: Trastuzumab (Herceptin®) is a monoclonal antibody used for the treatment of breast cancer. Experience with use of this agent during pregnancy, and its possible effects on the fetus, is limited. Case: We present a case of a patient with breast cancer who was treated with trastuzumab during the first 24 weeks of pregnancy. This treatment was associated with reversible maternal heart failure, which resolved slowly after the drug was discontinued, but with no adverse fetal effects and a normal infant examination at the age of 2 months. Updated literature review is discussed.

Original languageEnglish
Pages (from-to)611-613
Number of pages3
JournalReproductive Toxicology
Volume23
Issue number4
DOIs
StatePublished - Jun 2007
Externally publishedYes

Keywords

  • Breast cancer
  • Cancer treatment in pregnancy
  • Chemotherapy
  • Pregnancy
  • Teratology

Fingerprint

Dive into the research topics of 'Favorable pregnancy outcome following Trastuzumab (Herceptin®) use during pregnancy-Case report and updated literature review'. Together they form a unique fingerprint.

Cite this